Patients with metastatic ROS1-rearranged lung cancers typically derive substantial benefit from ROS1-targeted tyrosine kinase inhibitors (TKIs) such as crizotinib and entrectinib, often with marked initial tumor responses4,5. Here, ROS1 is linked to neoplasm.